Cancer Vaccines to Generate $ 7.7 Billion by 2015
This report concentrates on the cancer vaccines market, including antigen/adjuvant vaccines, whole cell tumor vaccines, dendritic cell (DC) vaccines, viral vectors and DNA vaccines, & idiotype vaccines
Rockville, MD, September 11, 2010 --(PR.com)-- MarketResearch.com has announced the addition of Kalorama Information’s new report “Emerging Cancer Vaccines: Forecasts, Developments and Pipeline Analysis, 4th Edition” to their collection of reports. For more information, visit:
http://www.marketresearch.com/product/display.asp?productid=2794580
The approval of Dendreon’s prostate cancer vaccine Provenge in April was a boon for a nascent cancer vaccine industry that had suffered several setbacks, and should lead to an influx of market opportunities and a surge in regulatory activity, according to Kalorama Information. In its newly published report, “Emerging Cancer Vaccines: Forecasts, Developments and Pipeline Analysis, 4th Edition,” the healthcare market research publisher notes that it believes a $7.7 billion market for cancer vaccines is a realistic estimate for 2015.
Kalorama believes the approval of Provenge by the FDA will likely reinstall investor confidence in cancer vaccines, which had been damaged by poor commercial results in previous therapeutic vaccine approvals and disappointing Phase III studies in other once promising products such as CancerVax's Canvaxin, Aphton's Insegia, Progenics' GMK vaccine, and Biomira's Theratope.
“This was a speculative market a decade ago, and one with its share of failed attempts,” said Melissa Elder, analyst for Kalorama Information. “Provenge’s approval and the cervical cancer vaccines represent real achievements for the therapeutic treatment of cancers using vaccines.”
Kalorama indicates that the response to Provenge has shown the market could become highly competitive within just a few years. The areas expected to display the highest competition, according to Kalorama’s research, include melanoma, lymphoma, cervical, renal and prostate cancer. These areas have a wide range of research and development activities brewing from preclinical trials to Phase III. Many of the products already in Phase III development have orphan drug status, SPA status, or Fast Track status. This provides a promising future for many of these products.
More information is available from Kalorama Information’s report, “Emerging Cancer Vaccines: Forecasts, Developments and Pipeline Analysis, 4th Edition,” which focuses on preventive and therapeutic cancer vaccines in development for a variety of cancers including cervical, colon/rectal, lung, lymphoma, melanoma, prostate, breast, gastrointestinal, renal, brain, bladder, ovarian and leukemia. The report details market forecasts through 2015, products in development, trends and issues impacting the industry, and key company profiles. For more information, visit:
http://www.marketresearch.com/product/display.asp?productid=2794580
Contact:
Veronica Franco
MarketResearch.com
vfranco@marketresearch.com
240.747.3016
###
http://www.marketresearch.com/product/display.asp?productid=2794580
The approval of Dendreon’s prostate cancer vaccine Provenge in April was a boon for a nascent cancer vaccine industry that had suffered several setbacks, and should lead to an influx of market opportunities and a surge in regulatory activity, according to Kalorama Information. In its newly published report, “Emerging Cancer Vaccines: Forecasts, Developments and Pipeline Analysis, 4th Edition,” the healthcare market research publisher notes that it believes a $7.7 billion market for cancer vaccines is a realistic estimate for 2015.
Kalorama believes the approval of Provenge by the FDA will likely reinstall investor confidence in cancer vaccines, which had been damaged by poor commercial results in previous therapeutic vaccine approvals and disappointing Phase III studies in other once promising products such as CancerVax's Canvaxin, Aphton's Insegia, Progenics' GMK vaccine, and Biomira's Theratope.
“This was a speculative market a decade ago, and one with its share of failed attempts,” said Melissa Elder, analyst for Kalorama Information. “Provenge’s approval and the cervical cancer vaccines represent real achievements for the therapeutic treatment of cancers using vaccines.”
Kalorama indicates that the response to Provenge has shown the market could become highly competitive within just a few years. The areas expected to display the highest competition, according to Kalorama’s research, include melanoma, lymphoma, cervical, renal and prostate cancer. These areas have a wide range of research and development activities brewing from preclinical trials to Phase III. Many of the products already in Phase III development have orphan drug status, SPA status, or Fast Track status. This provides a promising future for many of these products.
More information is available from Kalorama Information’s report, “Emerging Cancer Vaccines: Forecasts, Developments and Pipeline Analysis, 4th Edition,” which focuses on preventive and therapeutic cancer vaccines in development for a variety of cancers including cervical, colon/rectal, lung, lymphoma, melanoma, prostate, breast, gastrointestinal, renal, brain, bladder, ovarian and leukemia. The report details market forecasts through 2015, products in development, trends and issues impacting the industry, and key company profiles. For more information, visit:
http://www.marketresearch.com/product/display.asp?productid=2794580
Contact:
Veronica Franco
MarketResearch.com
vfranco@marketresearch.com
240.747.3016
###
Contact
MarketResearch.com
Veronica Franco
240.747.3016
www.marketresearch.com/
Veronica Franco
240.747.3016
www.marketresearch.com/
Contact
Categories